4 results
Primary Objective:To evaluate if treatment with RVX000222 as compared to placebo increases time to thefirst occurrence of narrowly defined MACE. Narrowly defined MACE is defined as a singlecomposite endpoint of CV death or non-fatal MI or stroke.…
The primary objective of this study is to assess the clinical efficacy of SC administration of golimumab in pediatric subjects (ages 2 to less than 18 years) with JIA manifested by more or equal to 5 joints with active arthritis despite MTX therapy…
Primary ObjectiveTo evaluate the effect of RVX000222 on the change in burden of coronary atherosclerosis, as measured by percent atheroma volume (PAV), in patients with coronary artery disease and a low level of HDL-C requiring angiography for a…
x To assess the safety and tolerability of MK-7240/PRA023 in SSc-ILD x To compare the annual rate of change from Baseline in forced vital capacity (FVC), in mL, of MK-7240/PRA023 vs. placebo over 50 weeks For more information please refer to…